Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDiaz, Ricardo Sobhie [UNIFESP]
dc.contributor.authorSucupira, Maria Cecilia A. [UNIFESP]
dc.contributor.authorVergara, Tania R. C.
dc.contributor.authorBrites, Carlos
dc.contributor.authorDel Bianco, Rosana
dc.contributor.authorBonasser Filho, Francisco
dc.contributor.authorColares, Geova Keny B.
dc.contributor.authorPortela, Estevao
dc.contributor.authorCherman, Lia Adler
dc.contributor.authorBarcelos, Nemora Tregnago
dc.contributor.authorTupinambas, Unai
dc.contributor.authorTurcato, Gilberto
dc.contributor.authorAllamasey, Lisa
dc.contributor.authorBacheler, Lee
dc.contributor.authorTuohy, Martin
dc.contributor.authorBrazilian Network Reference Phys W
dc.identifier.citationBrazilian Journal of Infectious Diseases. Salvador: Contexto, v. 14, n. 5, p. 489-494, 2010.
dc.description.abstractObjective: To investigates how the use of HIV-1 resistance tests influences physician decision-making. Methods: Ten experienced reference physicians from the Brazilian Network for Drug Resistance each received ten patients' case histories. the selected patients had experienced at least two virological failures. First, reference physicians were asked to empirically select a new regimen for each patient. Second, after genotype report (ViroSeq 2.6) was provided, and physicians were again asked to select a new regimen considering this additional information. Finally, they were asked to select a regimen after receiving a virtual phenotype result (vircoTYPE 3.9.00). Results: in 79% of the cases, physicians changed their empirical choice of regimen after receiving the genotype report, resulting in an increase in the mean number of active drugs from 1.8 to 2.2 (p = 0.0003), while the average number of drugs/regimen remained at 4.0. After receipt of the virtual phenotype report, additional changes were made in 75% of the patient cases, resulting in an increase in the number of active drugs to 2.8 (p < 0.0001), while the average number of drugs/regimen remained at 4.0. After receipt of the genotype report, 48% of the changes were in NRTIs, 29% were in NNRTIs and 60% were in PIs; after consideration of the virtual phenotype, 61%, 10% and 49% of the changes, respectively, were in these categories of drugs. Fourteen percent of the physicians rated the genotype report as extremely useful, whereas 34% rated the subsequent virtual phenotype report as extremely useful (p = 0.0003). Conclusions: Resistance testing has a significant impact on physicians' choices of antiretroviral salvage therapies, and it promotes the selection of more active drugs.en
dc.relation.ispartofBrazilian Journal of Infectious Diseases
dc.rightsAcesso aberto
dc.subjectvirtual phenotypeen
dc.subjectantiretroviral resistanceen
dc.titleHIV-1 resistance testing influences treatment decision-makingen
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade Federal da Bahia (UFBA)
dc.contributor.institutionHosp Emilio Ribas
dc.contributor.institutionUniv Fortaleza
dc.contributor.institutionFundacao Oswaldo Cruz
dc.contributor.institutionSecretaria Estadual Saude Rio Grande Sul
dc.contributor.institutionUniversidade Federal de Minas Gerais (UFMG)
dc.contributor.institutionVirco BVBA
dc.contributor.institutionVircoLab Inc
dc.description.affiliationUniversidade Federal de São Paulo, Retrovirol Lab, EPM, BR-04039 São Paulo, Brazil
dc.description.affiliationUniv Fed Bahia, BR-41170290 Salvador, BA, Brazil
dc.description.affiliationHosp Emilio Ribas, São Paulo, Brazil
dc.description.affiliationUniv Fortaleza, Fortaleza, Ceara, Brazil
dc.description.affiliationFundacao Oswaldo Cruz, Rio de Janeiro, Brazil
dc.description.affiliationSecretaria Estadual Saude Rio Grande Sul, Porto Alegre, RS, Brazil
dc.description.affiliationUniv Fed Minas Gerais, Belo Horizonte, MG, Brazil
dc.description.affiliationVirco BVBA, Mechelen, Belgium
dc.description.affiliationVircoLab Inc, Durham, NC USA
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Retrovirol Lab, EPM, BR-04039 São Paulo, Brazil
dc.description.sourceWeb of Science
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.